From Actelion's PR today an update on their IPF program
Bosentan (Tracleer®) in IPF: This multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven morbidity/mortality study (BUILD-3) is evaluating the safety and efficacy of bosentan 125mg bid in patients diagnosed with idiopathic pulmonary fibrosis. The original enrollment target of 390 patients was achieved in Q1 2008. An expansion of the study to include Japan and South Korea has resulted in more than 500 patients enrolled by the end of H1 2008. Enrollment is now expected to conclude later this year with around 600 patients. The study is expected to report final results towards the end of 2009.